Metabolomx test detects lung cancer from breath

December 15, 2011

Mountain View, CA - December 15, 2011 - Metabolomx, a diagnostic company focused on the detection of the metabolomics signature of cancer from exhaled breath, today announces publication of results from the first clinical study demonstrating a breath test that can both detect lung cancer and differentiate between types of lung cancer in humans. This seminal study, conducted at the Cleveland Clinic and led by Dr. Peter Mazzone, used Metabolomx' first-generation colorimetric sensor array, and reported accuracy exceeding 80% in lung cancer detection, comparable to computerized tomography (CT) scan. Further, the study found that Metabolomx' first-generation colorimetric sensor array could identify the subtype of lung cancer (small cell versus adenocarcinoma versus squamous cell) with accuracy approaching 90%.

The availability of a low-cost, non-invasive metabolomic breath signature for lung cancer is particularly timely given the recently announced results of the National Cancer Institute's National Lung Screening Trial (NLST) calling for wider CT screening of high-risk citizens. The breath signature, which reports active tumor metabolism, is thought to provide complementary information to CT, potentially helping clinicians distinguish benign from malignant lung nodules.

The sensor detects the unique pattern of volatile organic compounds (the "metabolic biosignature") present in exhaled breath. The article, "Exhaled Breath Analysis with a Colorimetric Sensor Array for the Identification and Characterization of Lung Cancer," is appearing in the current, online issue of the Journal of Thoracic Oncology (JTO), the official Journal of the International Association for the Study of Lung Cancer.

James R. Jett, MD, Pulmonary Medicine and Medical Oncology, National Jewish Health and Editor-in-Chief of the Journal of Thoracic Oncology, stated, "The JTO is dedicated to publishing the best in clinical research that may one day make a real difference in the care of patients. The currently reported results, should they be confirmed in additional clinical testing, provide a provocative challenge for us to look more closely at 'biosignatures,' as described in the journal article, that may be complementary to detection modalities such as CT scan. The advent of the NLST results demonstrating the value of CT heightens the need for non-invasive, low-cost companion diagnostics, and a metabolomic breath test, if born out in continuing studies, is a candidate to play that role in early lung cancer detection."

"The Cleveland Clinic results just published by the Journal of Thoracic Oncology, the reference journal for lung cancer, demonstrate the broad potential for use of breath analysis in the early detection of lung cancer," commented Paul Rhodes, PhD, Founder and CEO of Metabolomx. "These results show that the first generation of our breath test technology compares well with CT scans. Detection of the metabolomic signature of lung cancer in exhaled breath is non-invasive, rapid, and inexpensive, and will become a valuable adjunct to help assess an indeterminate CT, and may come to have a central role in early detection and differentiation of lung cancer, while lowering costs to the healthcare system."

The article was authored by Peter J. Mazzone, MD, MPH, Cleveland Clinic; Xiao-Feng Wang, PhD, Cleveland Clinic; Yaomin Xu, PhD, Cleveland Clinic; Tarek Mekhail, MD, MSc, Florida Hospital; Mary C. Beukemann, Cleveland Clinic; Jie Na, MS, Cleveland Clinic; Jonathan W. Kemling, PhD, University of Illinois, Chicago; Kenneth S. Suslick, PhD, University of Illinois, Chicago; and Madhu Sasidhar, MD, Cleveland Clinic. Initial results from this study were presented at the American College of Chest Physicians conference in November 2010.

Dr. Mazzone commented, "Our research shows that breath testing may help identify patients with lung cancer, as well as provide us with information that can help with treatment decisions, such as the type of lung cancer, its stage, and prognosis. The accuracy of these non-invasive tests can be further augmented when combined with existing clinical predictors, such as health status and age."

Metabolomx has begun trials of its next-generation sensor array system in an ongoing lung cancer study at the Cleveland Clinic. The Company expects their current generation system to be over 100 times more sensitive at detecting breath chemicals, which are often present in very low concentrations, than the system used in the published study.

About the Study

The study, conducted at the Cleveland Clinic and led by Dr. Peter Mazzone, was designed to develop an exhaled breath biosignature of lung cancer using Metabolomx' colorimetric sensor array and to determine the accuracy of breath biosignatures of lung cancer characteristics with and without the inclusion of clinical risk factors. Breath samples were drawn from 229 individuals, 92 with biopsy-proven, untreated lung cancer and 137 either at a risk for developing lung cancer or with indeterminate lung nodules. Logistic prediction models were developed and statistically validated based on the color changes of the sensor. Age, sex, smoking history, and chronic obstructive pulmonary disease were incorporated in the prediction models.

Key Study Results

-end-
About Metabolomx

Metabolomx has developed and owns all worldwide rights to the foremost breath test for cancer. By engaging some of the brightest minds in the fields of artificial and biological olfactory sensor arrays, neural processing and product development, Metabolomx has developed and tested an artificial olfactory sensor technology that recognizes the molecular fingerprint of the disease signature in breath. Metabolomx' technology is enabling the non-invasive, rapid, inexpensive and early diagnosis of lung cancer and other cancers. Metabolomx is located in Mountain View, CA. For additional information on the Company, please visit www.metabolomx.com.

Contacts

Media on behalf of Metabolomx
Justin Jackson
Michelle Szwarcberg
Burns McClellan
Tel: +1-212-213-0006
Email: jjackson@burnsmc.com
mszwarcberg@burnsmc.com

Burns McClellan

Related Lung Cancer Articles from Brightsurf:

State-level lung cancer screening rates not aligned with lung cancer burden in the US
A new study reports that state-level lung cancer screening rates were not aligned with lung cancer burden.

The lung microbiome may affect lung cancer pathogenesis and prognosis
Enrichment of the lungs with oral commensal microbes was associated with advanced stage disease, worse prognosis, and tumor progression in patients with lung cancer, according to results from a study published in Cancer Discovery, a journal of the American Association for Cancer Research.

New analysis finds lung cancer screening reduces rates of lung cancer-specific death
Low-dose CT screening methods may prevent one death per 250 at-risk adults screened, according to a meta-analysis of eight randomized controlled clinical trials of lung cancer screening.

'Social smokers' face disproportionate risk of death from lung disease and lung cancer
'Social smokers' are more than twice as likely to die of lung disease and more than eight times as likely to die of lung cancer than non-smokers, according to research presented at the European Respiratory Society International Congress.

Lung cancer therapy may improve outcomes of metastatic brain cancer
A medication commonly used to treat non-small cell lung cancer that has spread, or metastasized, may have benefits for patients with metastatic brain cancers, suggests a new review and analysis led by researchers at St.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Lung transplant patients face elevated lung cancer risk
In an American Journal of Transplantation study, lung cancer risk was increased after lung transplantation, especially in the native (non-transplanted) lung of single lung transplant recipients.

Proposed cancer treatment may boost lung cancer stem cells, study warns
Epigenetic therapies -- targeting enzymes that alter what genes are turned on or off in a cell -- are of growing interest in the cancer field as a way of making a cancer less aggressive or less malignant.

Are you at risk for lung cancer?
This question isn't only for people who've smoked a lot.

Read More: Lung Cancer News and Lung Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.